Agenus Inc (AGEN)

6.11
0.26 4.40
NASDAQ : Health Care
Prev Close 5.85
Open 5.94
Day Low/High 5.85 / 6.13
52 Wk Low/High 2.61 / 7.45
Volume 460.81K
Avg Volume 1.04M
Exchange NASDAQ
Shares Outstanding 87.00M
Market Cap 526.35M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Agenus To Report Second Quarter 2016 Financial Results On July 28, 2016; Conference Call To Follow

Agenus To Report Second Quarter 2016 Financial Results On July 28, 2016; Conference Call To Follow

Agenus Inc. (NASDAQ: AGEN) will release its second quarter 2016 financial results before the market opens on Thursday, July 28, 2016.

Kamich's 10 Stocks Under $10

Kamich's 10 Stocks Under $10

This list was driven by the charts, but do your homework and fundamental research before you jump in.

Agenus Appoints Jean-Marie Cuillerot, M.D. As Vice President And Global Head Of Clinical Development (Photo: Business Wire)

Agenus Appoints Jean-Marie Cuillerot, M.D. As Vice President And Global Head Of Clinical Development (Photo: Business Wire)

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced the appointment of Jean-Marie...

Agenus Announces Commencement Of Phase 1/2 Clinical Trial Of Anti-GITR Checkpoint Antibody INCAGN1876 In Patients With Solid Tumors

Agenus Announces Commencement Of Phase 1/2 Clinical Trial Of Anti-GITR Checkpoint Antibody INCAGN1876 In Patients With Solid Tumors

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the first patient has been dosed in a...

First Week of February 2017 Options Trading For Agenus (AGEN)

First Week of February 2017 Options Trading For Agenus (AGEN)

Investors in Agenus Inc saw new options become available this week, for the February 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Agenus Charts Shows Upside Potential

This low-priced health care stock looks better on the charts.

Agenus To Present At The 2016 JMP Securities Life Sciences Conference

Agenus To Present At The 2016 JMP Securities Life Sciences Conference

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Robert B.

Put Agenus, Progenics on Your Small-Cap List

Both have good capital appreciation potential.

Put Agenus, Progenics on Your Small-Cap List

Both have good capital appreciation potential.

Trade-Ideas: Agenus (AGEN) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Agenus (AGEN) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Agenus (AGEN) as a strong on high relative volume candidate

Agenus Announces Lead Product Candidate Selection In Its Collaboration With Merck

Agenus Announces Lead Product Candidate Selection In Its Collaboration With Merck

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators (CPMs) and cancer vaccines, today announced the selection of a lead product...

Agenus To Webcast Annual Meeting Of Stockholders

Agenus To Webcast Annual Meeting Of Stockholders

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, invites investors and the general public to its Annual...

Agenus (AGEN) Stock: Weak On High Volume Today

Agenus (AGEN) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Agenus (AGEN) as a weak on high relative volume candidate

Agenus To Present At The Jefferies 2016 Healthcare Conference

Agenus To Present At The Jefferies 2016 Healthcare Conference

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Garo H.

Agenus Appoints Ulf Wiinberg To Board Of Directors

Agenus Appoints Ulf Wiinberg To Board Of Directors

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced the appointment of Ulf Wiinberg to the...

Agenus Reports First Quarter 2016 Financial Results And Operational Progress

Agenus Reports First Quarter 2016 Financial Results And Operational Progress

Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.

Agenus Commences Phase 1 Clinical Trial Of Its CTLA-4 Checkpoint Antibody To Treat Solid Tumors

Agenus Commences Phase 1 Clinical Trial Of Its CTLA-4 Checkpoint Antibody To Treat Solid Tumors

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in the company's Phase 1 clinical trial of AGEN1884, an...

Agenus To Report First Quarter 2016 Financial Results On April 28, 2016; Conference Call To Follow

Agenus To Report First Quarter 2016 Financial Results On April 28, 2016; Conference Call To Follow

Agenus Inc. (NASDAQ: AGEN) will release its first quarter 2016 financial results before the market opens on Thursday, April 28, 2016.

First Week of June 17th Options Trading For Agenus (AGEN)

First Week of June 17th Options Trading For Agenus (AGEN)

Investors in Agenus Inc saw new options become available this week, for the June 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGEN options chain for the new June 17th contracts and identified one put and one call contract of particular interest.

Agenus Presents Posters On Checkpoint Antibody Product Candidates At The American Association For Cancer Research (AACR) 2016 Annual Meeting

Agenus Presents Posters On Checkpoint Antibody Product Candidates At The American Association For Cancer Research (AACR) 2016 Annual Meeting

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, today announced that three abstracts on the Company's checkpoint modulator product candidates were...

Agenus (AGEN) Strong On High Relative Volume Today

Agenus (AGEN) Strong On High Relative Volume Today

Trade-Ideas LLC identified Agenus (AGEN) as a strong on high relative volume candidate

Agenus To Participate At Three Upcoming Oncology Conferences

Agenus To Participate At Three Upcoming Oncology Conferences

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, today announced participation at the following conferences: The 6 th Annual...

Interesting AGEN Put And Call Options For November 18th

Interesting AGEN Put And Call Options For November 18th

Investors in Agenus Inc saw new options begin trading this week, for the November 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Strong On High Volume: Agenus (AGEN)

Strong On High Volume: Agenus (AGEN)

Trade-Ideas LLC identified Agenus (AGEN) as a strong on high relative volume candidate

Biotech Rally Is Healing Small-Caps

This sector is finally bouncing from deeply oversold levels.

Noteworthy Thursday Option Activity: AGEN, FTD, CHK

Noteworthy Thursday Option Activity: AGEN, FTD, CHK

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Agenus Inc , where a total volume of 7,626 contracts has been traded thus far today, a contract volume which is representative of approximately 762,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 72.3% of AGEN's average daily trading volume over the past month, of 1.1 million shares.

Agenus (AGEN) Stock Climbs Despite Q4 Miss

Agenus (AGEN) Stock Climbs Despite Q4 Miss

Agenus (AGEN) stock is gaining on Thursday afternoon despite the release of lower-than-expected 2015 fourth quarter results.

Agenus Reports Fourth Quarter And Full Year 2015 Financial And Operational Results And Recent Highlights

Agenus Reports Fourth Quarter And Full Year 2015 Financial And Operational Results And Recent Highlights

Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, today provided a corporate update and reported financial results for the fourth quarter and year ended...